O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus

O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus

Bibliographic Details
Main Authors: Laura Geraldino-Pardilla, Subhashis Banerjee, Ann E Clarke, Eric Morand, Cristina Arriens, Ronald van Vollenhoven, Coburn Hobar, Samantha Pomponi, Ravi Koti, Thomas Wegman
Format: Article
Language:English
Published: BMJ Publishing Group 2024-03-01
Series:Lupus Science and Medicine

Similar Items